Immunyx Pharma USA Inc.
Publicly observedNew York, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | New York | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Immunyx Pharma USA Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | SLHND6A732S3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of IMYX-3 for the Treatment of Ulcerative Colitis
USD 981,715.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of IMYX-3 for the Treatment of Ulcerative Colitis
USD 1,024,862.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.